Credit: Hananeko_Studio via Shutterstock. Agomab Therapeutics has secured $89m in Series D funding to support clinical trials of its fibrotic disease treatments, with some help from Sanofi.

CAL101 is a monoclonal antibody targeting the S100A4 protein for the treatment of fibrotic and fibro-inflammatory diseases. Credit: JOURNEY STUDIO7 / Shutterstock. Calluna Pharma has concluded the ...

These results are an important step forward in the development of our lead asset, CAL101, particularly for fibrotic and fibro-inflammatory diseases where there remains a critical need for innovative ...